Biogen criticized in the US over price of new Alzheimer's drug

Bloomberg News reports that treating 1 million patients will cost around USD 57bn annually according to an estimate made by the Kaiser Family Foundation.

BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The price tag of Biogen's new Alzheimer's medication Aduhelm has raised criticism and concern in the US. Soon, authorities will decide the extent of the available support schemes and the patient groups that will be offered the medication, according to Bloomberg News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Biogen partner calls for global Alzheimer's effort
For subscribers
Sage Therapeutics depression drug disappoints
For subscribers
FDA advisors quit after approval of Alzheimer's medicine
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers
Novo Nordisk suffers Wegovy defeat to Viatris in patent court
It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees
The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.
For subscribers
Pharmaceutical industry to grow 4% annually towards 2030
However, there is one company in the manufacturing sector that is predicted to see negative growth.
For subscribers

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers

Novo Nordisk's manufacturing facility in Clayton, the US. | Photo: Novo Nordisk/pr

Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers

Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers